Apogee Therapeutics, Inc. 4

Fairmount Healthcare Fund II L.P., together with managers Tomas Kiselak and Peter Harwin, had all of their Apogee Therapeutics common, non-voting common, and stock options cashed out at $135.11 per share in connection with AbbVie’s merger, leaving them with no remaining holdings.

On September 3, 2026, Fairmount Healthcare Fund II L.P., together with its managers Tomas Kiselak and Peter Harwin, reported the cash-out of all of their Apogee Therapeutics, Inc. equity positions in connection with AbbVie Inc.’s acquisition of the company under a merger agreement that provided $135.11 per share in cash. The fund’s 340,855 shares of common stock, 6,743,321 non-voting common shares (convertible 1:1 into common stock subject to ownership caps), and Kiselak’s and Harwin’s individual holdings of 51,166 common shares each were all disposed of for cash at the merger price. In addition, four tranches of stock options held by Kiselak with exercise prices ranging from $17.00 to $85.00 per share over a total of 80,246 underlying shares became fully vested and were cancelled for cash equal to the spread between $135.11 and the respective exercise prices. After these merger-related dispositions, the reporting persons no longer held Apogee equity, and they each disclaimed beneficial ownership of the securities beyond their pecuniary interests, with Fairmount and its fund potentially deemed directors by deputization due to Kiselak’s board service.

Filing Facts

CIK

1974640

Ticker

APGE

Form

4

Source Type

fda

Accession

0001104659-26-105119

Alert Tier

6